# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, P...
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996...
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run c...
Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns...
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.